Clinical Trial Update: An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections [Phase 3]

View source ↗

Summary

Open-label Phase III multicenter trial evaluating voriconazole for invasive fungal infections has completed. The study assessed efficacy, safety and tolerabilit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aspergillosis
• Candidiasis
• Fungemia
• Mycoses

Drugs mentioned

• VORICONAZOLE (Voriconazole)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Aspergillosis, Candidiasis | Phase 3 | Status: COMPLETED